For all-cause mortality and cancer recurrence, only differences in percentage of low-grade cancers between ARID1A− vs. ARID1A+, country, and number of adjustments were significant moderators, while for adjusted hazard ratios no significant moderators were evident (Supplementary Table 3). This evidence concerns the gene ARID1A and cancer.